Therapeutic areas

Health economics

Arthritis and immunology

In this rapidly evolving area, gaps in available evidence must be addressed in a proactive way that captures treatment nuances. We apply patient-level simulation, health-related quality of life mapping, and other advanced methods of technical analysis to provide customised solutions for gaining market access for your drug.

We have assisted clients in winning market access for several blockbuster medicines in idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis and other auto-immune conditions. During this work, we have spearheaded highly cited research publications and successful submissions to health technology assessment (HTA) bodies.

Success story: supporting the global market access strategy for an immunology drug.


Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. (2019) ‘Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterology6:e000302.

Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, et al. (2014) ‘Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK’. Pharmacoeconomics; 32(8):775-87.

Evidence development

Cardiometabolic health

Cardiometabolic diseases are the most common cause of death around the world. While advances in medicine have improved the treatment and management of these conditions, their global prevalence continues to grow.

We can help you bring game-changing treatments to patients faster. We have produced numerous global cost-effectiveness models for medicines and devices in this area for clients in the UK, US and farther afield. Our work has led to several highly cited research publications and successful submissions to HTA bodies.

Success story: evaluating the cost-effectiveness of a diagnostic device.


Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener HC. (2016) ‘Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke’. International Journal of Stroke11(3):302-12.

Health economics


Dermatological conditions may not be life-threatening, but they can have a debilitating impact on patients’ quality of life.

We can help you perform industry-leading research in this area, develop convincing pricing strategies as well as navigate complex, constantly evolving HTA processes – giving your drug or device the best chances of market access. Working in dermatological conditions such as psoriasis and atopic dermatitis, we have spearheaded several highly cited publications, developed numerous global models and adapted them to specific countries. We have conducted network meta-analyses appraised by industry peers at the Professional Society for Health Economics and Outcomes Research (ISPOR) as an innovative way to overcome missing data.

Success story: overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments.


Sawyer LM, Malottki K, Sabry-Grant CYasmeen N, et al. (2019) ‘Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response’. PLoS One14(8):e0220868.

Wright E, Yasmeen N, Malottki K, Sawyer LM, Borg E, Schwenke C, Warren RB. (2021) ‘Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?’. Dermatology and Therapy; 11:181-220.

Health economics

Neurology & mental health

When dealing with an organ as complex as the brain, you need a partner with unrivalled experience in evidence reviews and economic modelling in order to rise above the complexity and chart a course for your drug or device.

We can help you navigate the complexities of mental health and neurological conditions and the intricacies of available evidence within this area in order to streamline your decision-making and optimise your approach to the market. We have helped our international clients anchor their research and development for neurological conditions such as dementia and epilepsy. We also have deep experience demonstrating the value of interventions against mental health conditions including bipolar disorder, depression, and schizophrenia.

Success story: we supported a device manufacturer with early-stage value demonstration in epilepsy.


Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, Hansen K. (2014) ‘Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. Journal of Medical Economics17(7):508-19.

Raspin C, Shankar R, Barion F, Pollit V, Murphy J, Sawyer L, Danielson V. (2021) ‘An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England, “24(1):1037-1051.

Health economics


Cancer is the target of a substantial share of new medicines that enter the market, and this share continues to grow. Likewise, a large share of our work at Symmetron focuses on oncology. We have helped clients in Canada, Ireland, the UK, and to gain market access for their drugs against breast, colorectal, lung, thyroid, lymphoma, and other cancers.

Success story: overcoming limited evidence to gain reimbursement for a blockbuster oncology drug.


Sabry-Grant C, Malottki K, Diamantopoulos A. (2019) The Cancer Drugs Fund in Practice and Under the New Framework. Pharmacoeconomics; 37(7):953-962.

Health economics

Policy and methods

Experts at Symmetron have followed career paths in government, academia and industry, and our diversity makes us uniquely suited to analyse healthcare challenges from a 360-degree perspective. We believe that good consulting practice means identifying industry needs and seeking to address them.

We have carried out industry-leading research in numerous areas of healthcare that cut across several therapeutic areas, including medicines access, outcomes-based contracts, global HTA requirements, patient priority outcomes, and HTA for immune-oncology medicines. This is all part of our core mission of helping clients bring medicines and devices to market in order to increase healthcare access and improve patients’ quality of life.

Success story: understanding the role of patient centred outcomes in health technology assessment (HTA).


Halsby K, Langford B, Pagotto A, Tuson H, Collings S-L,1 Gonçalves-Bradley D, Yasmeen N, Burton J. A Framework And Analysis Assessing The Impact Of Patient-Centred Outcome Evidence In HTA Appraisals. Health Technology Assessment International. 2021.

Health economics

Rare diseases

Rare diseases lack the large market to attract certain kinds of investment, yet many are debilitating and reflect inequities in global healthcare.

We help clients who have the courage and flexibility to step into this less-chartered territory by helping them assess the underdeveloped evidence base. For this work, we sometimes draw on the award-winning methods and strategies that we have developed to understand and overcome evidence gaps related to major diseases. Occasionally, however, we need to apply or even innovate new methods that take into account the particularities of rare conditions. We have helped clients target a broad range of rare diseases, including anaemia, haematology, respiratory conditions, idiopathic pulmonary fibrosis, progressive medullary thyroid cancer, giant cell arthritis, and haemophilia B.

Success story: modelling long-term survival for rare disease patients after the trial period.


Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. (2018) ‘The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review’. PharmacoEconomics; 36:779–807.

Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. (2017) ‘A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics; 35(4):479-491.